Table 2 |
||||
|
Hazard ratios of mortality according to baseline variables in HIV-infected patients starting ART in Tanzania |
||||
|
Unadjusted |
Adjusteda |
|||
|
|
||||
|
Baseline variables |
HR (95% CI) |
P |
HR (95% CI) |
P |
|
|
||||
|
Gender (male vs. female) |
1.73 (1.15–2.61) |
0.009 |
1.60 (1.00–2.57) |
0.053 |
|
WHO stage (IV vs. I–III) |
2.71 (1.64–4.49) |
<0.001 |
1.46 (0.81–2.65) |
0.210 |
|
ART start year (vs. 2003–04) |
||||
|
2005 |
0.55 (0.35–0.87) |
0.010 |
0.64 (0.38–1.08) |
0.091 |
|
2006 |
0.30 (0.17–0.56) |
<0.001 |
0.40 (0.19–0.83) |
0.014 |
|
BMI (vs. ≥ 18.5 kg/m2) |
||||
|
<16 |
4.17 (2.29–7.60) |
<0.001 |
2.12 (1.06–4.24) |
0.034 |
|
16–18.4 |
1.60 (0.82–3.10) |
0.168 |
1.27 (0.62–2.61) |
0.516 |
|
Hemoglobin (vs. ≥ 12 g/dL for women and ≥ 13 for men) |
||||
|
<8 |
22.7 (5.40–95.7) |
<0.001 |
9.20 (2.05–41.3) |
0.004 |
|
8–9.9 |
13.5 (3.28–55.9) |
<0.001 |
7.50 (1.77–31.9) |
0.006 |
|
10–11.9 (10–12.9 for men) |
6.21 (1.46–26.5) |
0.014 |
4.03 (0.93–17.5) |
0.063 |
|
TLC (vs. ≥ 1.2 × 109/L) |
||||
|
<0.6 |
3.58 (2.05–6.24) |
<0.001 |
1.72 (0.87–3.39) |
0.117 |
|
0.6–1.1 |
1.10 (0.69–1.74) |
0.699 |
0.79 (0.48–1.32) |
0.371 |
|
Platelet count (<150 vs. ≥ 150 × 109/L) |
2.23 (1.40–3.57) |
0.001 |
2.30 (1.33–3.99) |
0.003 |
|
|
||||
|
aCox proportional hazards model adjusted for all variables listed in the table. HR, hazard ratio; CI, confidence interval; ART, antiretroviral therapy; WHO, World Health Organization; BMI, body mass index; TLC, total lymphocyte count. |
||||
|
Johannessen et al. BMC Infectious Diseases 2008 8:52 doi:10.1186/1471-2334-8-52 |
||||
